Table 5. Univariate and multivariate analysis of progression-free survival in patients with metastatic nasopharyngeal carcinoma patients (PSM matched data).
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Sex | 0.056 | ||||
| Female vs. male | 0.57 (0.33–1.01) | ||||
| Age, years | 0.55 | ||||
| >50 vs. ≤50 | 1.14 (0.75–1.73) | ||||
| T classification | |||||
| T1 | 1 | ||||
| T2 | 0.87 (0.40–1.89) | 0.722 | |||
| T3 | 1.03 (0.51–2.09) | 0.928 | |||
| T4 | 0.78 (0.38–1.57) | 0.480 | |||
| N classification | 0.02 | ||||
| N1 | 1 | ||||
| N2 | 1.04 (0.43–2.51) | 0.938 | |||
| N3 | 1.89 (0.82–4.39) | 0.138 | |||
| Histology | |||||
| I | 1 | ||||
| II | 0.88 (0.32–2.38) | 0.794 | |||
| III | 2.06 (0.28–14.97) | 0.475 | |||
| ECOG | 0.662 | ||||
| 1 vs. 0 | 0.89 (0.52–1.52) | ||||
| IMRT | 0.165 | ||||
| Yes vs. no | 0.73 (0.47–1.14) | ||||
| SII | 0.003 | 0.003 | |||
| ≥930 vs. <930 | 1.84 (1.23–2.77) | 1.84 (1.23–2.77) | |||
ECOG, Eastern Cooperative Oncology Group performance; IMRT, intensity modulated radiotherapy; HR, hazard ratio; CI, confidence interval. SII, systemic immune-inflammation index.